Additionally, we demonstrate the possible utility of beta-arrestin-1 as a plasma biomarker for non-invasive diagnosis of lung cancer and report preliminary results suggesting that beta-arrestin-1 could be useful to predict tumour’s response to epidermal growth factor receptor (EGFR) inhibitor therapy. This evidence concerns the gene ARRB1 and neoplasm.